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 ABSTRACT 
Background and aim: Lipoprotein-apheresis (LA) is a therapeutic approach used against severe forms 
of dyslipidemia in patients who are non-responders or intolerant to pharmacological treatments. 
However, little is known about the potential pleiotropic effects of LA, particularly regarding the 
immune system and its regulation. Thus, in an attempt to analyse the potential effects of 
dyslipidemia and LA on the regulation of CD4
+
 T cells activation and lineage differentiation, we 
compared the CD4
+
 T cells cytokines secretion profiles of dyslipidemic patients before and after LA 
with the profiles observed in healthy donors.  
Methods: CD4
+
 T cells were isolated from 5 LA patients and 5 healthy donors and activated with anti-
CD3 or anti-CD3 + anti-CD46 antibodies. The supernatants were collected after 36h incubation and 
levels of secreted cytokines analysed by flow cytometry.  
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Results: Our results revealed a deep remodelling of CD4
+
 T cells cytokines secretion patterns in 
dyslipidemic patients compared to healthy donors, as reflected by a 15 times higher IFN-γ secretion 
rate after CD3 + CD46 co-activation in dyslipidemic patients after LA compared to healthy subjects  
and 8 times higher after CD3 activation alone (p=0.0187 and p=0.0118 respectively). Moreover, we 
demonstrated that LA itself also modifies the phenotype and activation pattern of CD4
+
 T-cells in 
dyslipidemic patients.  
Conclusion: These observations could be of fundamental importance in the improvement of LA 
columns/systems engineering and in developing new therapeutic approaches regarding dyslipidemia 
and associated pathologies such as atherosclerosis and type 2 diabetes. 
Keywords: dyslipidemia; lipoprotein-apheresis; cytokines; innate and adaptive immunity; CD4
+ 
T cells 
INTRODUCTION 
Patients with severe forms of dyslipidemia are subject to atherosclerosis and subsequent coronary 
ischemic events and thus require an intensive, effective, continuous, and personalized form of 
treatment [1]. Therefore, patients who are poor- or non-responders, or intolerant to pharmacological 
treatments require alternative therapeutic approach such as LA. In Germany, LA is currently 
representing the treatment of choice for patients not reaching the target levels of LDL-C under a 
maximum cholesterol lowering treatment approach such as PCSK9 inhibitors, and patients suffering 
from elevated lipoprotein(a) (Lp(a)). In other countries, LA is only performed to a very limited extent, 
mainly in patients with homozygous familial hypercholesterolemia (HoFH). 
The extracorporeal treatment is highly effective, but may exert additional effects by triggering an 
immunologic response via blood–biomaterial interactions. Recent investigations confirmed that LA 
not only show acute lipid-lowering and cholesterol-lowering effects, but also efficacy in reducing 
several plasmatic pro-inflammatory cytokines. On the other hand, there is evidence that the 
complement system, postulated to be of pathogenic importance for development of atherosclerotic 
lesions [2 [2-10]], gets activated by LA treatment due to bio-incompatibility and thus increases the 
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amount of systemic complement activation products [3]. However, there is also data suggesting that 
surfaces might bind complement components thereby reducing complement activation during the LA 
process [4]. These non-lipid-lowering effects can be defined as pleiotropic or pleiotropic-equivalent 
and may be both pro- and anti-inflammatory. The net result of these reactions is important to the 
patient [5] and measures to attenuate the inflammatory responses elicited by the extracorporeal 
treatment should be taken to obtain optimal bio-compatibility. 
The presence of T cells in human atherosclerotic plaques has been described in 1985 [6]. A few years 
later, MHC class II and IFN-γ were found in lesions, and antibodies to oxidized low-density lipoprotein 
(LDL) were described [7]. Today, the concept that atherosclerosis is an inflammatory disease is no 
longer controversial [8], and investigations on how this inflammation is regulated have emerged. In 
this regard, T cells are of particular interest, both because of their secretion of mediators that 
influence plaque development and because their activity depends on the triggering of specific 
antigens that are found within the disease site. T cells are regulated by soluble and membrane-bound 
molecules from many cell types and, in turn, they act on most other cells. This network of cell-to-cell 
interactions affects the development of many inflammatory and autoimmune diseases. 
In this context, we decided to investigate the potential effects of dyslipidemia and LA on the 
regulation of CD4
+
 T cells activation and induction in dyslipidemic patients, with a particular regard 
on the pro- / anti-inflammatory secreted cytokines balance. 
MATERIAL AND METHODS 
Patients and ethics 
The study was reviewed by the local ethics committee and all subjects gave written informed 
consent. In a pilot approach, a total number of 5 patients undergoing stable weekly LA treatment at 
the Extracorporeal Treatment and Apheresis Center of the University Hospital Carl Gustav Carus in 
Dresden were investigated. To perform the analyses, heparinized blood was collected immediately 
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prior to and following a single LA session. Samples were sent to King’s College London for further 
analysis. All findings were compared to an age- and gender-matched healthy cohort. 
Reagents 
Cell-stimulating mAbs were purified from a specific hybridoma (anti-CD3; OKT-3) or generated in-
house (anti-CD46; TRA-2-10) [9].  
T cell isolation and activation 
PBMCs were separated to CD4
+ 
T cells using the MACS human CD4
+
 Positive T Cell Isolation Kit 
(Miltenyi Biotech Ltd, Bisley, UK) according to manufacturer’s instructions. Purity of isolated 
lymphocyte fraction was typically >97 %. CD4
+
 T cells were activated by 36 h incubation at 37°C in 
complete RPMI medium in 48-well culture plates (2.5 – 3.0 x 10
5
 cells/well) coated with mAbs to CD3 
or CD3 + CD46 (2.0 μg/ml PBS each) and addition of 25 U/ml rhIL-2. 
Cytokine measurements 
Cytokine production and secretion by CD4
+
 T cells was measured using the Th1/Th2/Th17 Cytokine 
Bead Array kit (560484, BD Biosciences) according to manufacturer’s instructions and a LSR Fortessa 
Cytometer (BD Biosciences). 
Statistics 
Numerical data are presented with mean and standard error mean (SEM). Levels before LA versus 
after LA or versus healthy donors were compared by unpaired t tests. All tests were two tailed, and 
results with p<0.05 were considered statistically significant (*). Analyses were performed using 
PRISM 6 (Graph Pad Software Inc, La Jolla, CA). 
RESULTS 
Dyslipidemia and LA have an important impact on the release of pro-inflammatory markers by 
activated CD4
+
 T cells 
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Among pro-inflammatory cytokines secreted by activated CD4
+
 T cells, we found IFN-γ to be 
significantly over secreted in all the conditions of activation in patients with dyslipidemia before and 
after LA compared to healthy donors. IFN-γ secretion rate after CD3 + CD46 co-activation was 15 
times higher in dyslipidemic patients after LA compared to healthy subjects and 8 times higher after 
CD3 activation alone (FIG 1A). We also observed a 4 times increase in IFN-γ secretion by CD4
+
 T cells 
after CD3 and CD3 + CD46 activation in dyslipidemic patients before LA.  These results suggests that 
dyslipidemia is directly correlated with an important increase in IFN-γ secretion by CD3 and CD3 + 
CD46 activated T cells and that this effect is amplified by LA.  
Even if not statistically significant, we observed a clear tendency for IL-2 to be over secreted in CD4
+
 T 
cells from dyslipidemic patients compared to healthy donors, mostly after CD3 + CD46 co-activation 
(FIG 1B). As expected, the levels of IL-2 were barely detectable in non-activated and CD3 activated 
cells, but were slightly increased in cells from healthy donors after CD3 + CD46 activation. 
Surprisingly, the levels measured in cells from dyslipidemic patients before and after LA were 
respectively 30 and 45 times more elevated compared to healthy donors.  
Finally, we observed that IL-17A secretion induced by CD3 and CD3 + CD46 activation in CD4
+
 T cells 
is increased in dyslipidemic patient before and after LA compared to healthy donors (FIG 1C). As 
expected, IL-17A was not secreted either by non-activated or activated CD4
+
 T cells in healthy donors 
but surprisingly, we observed an increase of IL-17A secretion by cells isolated from dyslipidemic 
patients after CD3 activation. This effect was slightly, but not significantly amplified by LA. 
Interestingly, after CD3 + CD46 activation, the IL-17A secretion rates doubled compared to CD3 
activation alone. 
In all the conditions of activation, TNF-α secretion rates were slightly higher in the LA patients 
compared to healthy donors, but the difference did not reach a statistical significance. Therefore, our 
results demonstrate that LA does not induce a significant increase in TNF-α secretion by activated 
CD4
+
 T cells (FIG 1D). However, it is interesting to observe that when compared to healthy donors, 
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the rates of TNF-α secretion in dyslipidemic patients are slightly increased before LA and go back to 
nearly normal values after treatment (FIG 1D), potentially unravelling an influence of LA on TNF-α 
secretion pathways in activated CD4
+
 T cells. 
IL-6 secretion patterns were analysed in our experimental model and unexpectedly, our results 
suggest that CD4
+
 T cells from patients with dyslipidemia treated with LA have lower IL-6 secretion 
rates than healthy donors either when non-activated, but also after CD3 and CD3 + CD46 activation. 
Furthermore, there was a decrease of IL-6 secretion from cells isolated from LA patients after 
treatment (FIG 2A). It has to be noted that concerning the IL-6 secretion patterns from our 5 
dyslipidemic patients, 2 groups could be clearly distinguished (FIG 2B) with an opposite effect of LA 
inducing either a moderate to high decrease in IL-6 secretion for 3 patients (left panel) and a slight or 
moderate increase for the other 2 (right panel). 
Dyslipidemia and LA impact the release of anti-inflammatory cytokines IL-10 and IL-4 
While not significant in this limited cohort, differences seem to develop in IL-10 secretion between 
cells from dyslipidemic and healthy donors after CD3 and CD3 + CD46 activation. After CD3 
activation, CD4
+
 T cells from patients before LA secreted 4 times more IL-10 than cells from healthy 
donors and this increase was amplified to 5 times in the same patients after LA (FIG 3A). As expected, 
CD3 + CD46 activation increased IL-10 secretion in healthy donors as well as in dyslipidemic patients 
but surprisingly, this augmentation was more marked in dyslipidemic patients after LA, with values 6 
times higher than in healthy donors (FIG 3A). 
In this setting, IL-4 secretion from activated CD4
+
 T cells was only slightly increased in LA patients 
either before or after treatment when compared to healthy donors for which IL-4 secretion was null 
in all the conditions as expected (FIG 3B). Nevertheless, regarding the very low amounts of IL-4 
secreted in our experimental conditions, we can interrogate about the physiological relevance of this 
observation. 
DISCUSSION 
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In this pilot study, we compared the cytokines secretion profiles from CD4
+
 T cells isolated from 5 
healthy donors and from 5 dyslipidemic patients before and after LA. The secretion profiles were 
analysed after CD3 (TCR alone) and CD3 + CD46 co-activation, with a particular regard on the pro- / 
anti-inflammatory cytokines balance and on the NLRP3 inflammasome activation, since a 
complement-NLRP3 axis in CD4
+
 T cells has been recently described as a novel potential therapeutic 
target for the modulation of Th1 activity in autoimmunity and infection in humans [10].  
Dyslipidemia promotes alterations in CD3 + CD46 co-activation mechanisms in CD4
+ 
T cells 
In humans, CD46 is a widely distributed transmembrane glycoprotein that inhibits complement 
activation on host cells and CD46 engagement was shown to induce low IFN-γ, and high IL-10 in naïve 
CD3-activated CD4
+
 T cells, a phenotype shared with Tr1 cells. Therefore, CD46 plays an important 
role in the regulation of adaptive immunity and his deficiency is associated with chronic 
inflammation and autoimmune diseases [11]. Surprisingly, in LA patients, CD46 co-activation of CD4
+
 
T cells induced an important increase in IFN-γ secretion. This effect could be due to a dysfunction in 
the CD46-dependant signalling pathways in activated CD4
+
 T cells and could induce their incapacity to 
switch from a Th1 to a Tr1 phenotype, thus promoting a deleterious inflammatory state in patients 
with dyslipidemia. More importantly, this effect tends to be amplified by LA (p=0.0643). In parallel, 
IL-2 secretion rates were significantly increased after CD46 co-activation in LA patients compared to 
healthy donors and this effect also tends to be amplified by the treatment. This could be related to 
deleterious biomaterial interactions which promote activation of signalling pathways inducing pro-
inflammatory cytokines secretion in CD4
+
 T cells.  
Pro-inflammatory cytokines secretion by activated CD4
+
 T cells is globally increased in dyslipidemic 
patients and LA tends to amplify this effect 
The pro-inflammatory cytokines investigated herein included IFN-γ, IL-2, IL17A, TNF-α  and IL-6. 
The principal Th1 cytokine, IFN-γ, is produced by most T cells, including CD4
+
, in the human 
atherosclerotic plaque [7]. IFN-γ potentiates most stages that lead to inflammation in atherosclerosis 
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[12] but surprisingly, a study demonstrated that LDLR
−/−
 mice transplanted with bone marrow from 
IFN-γ
−/−
 mice exhibited larger atherosclerotic lesions than mice that received bone marrow from IFN-
γ
+/+
 mice [13], implicating a protective role of IFN-γ which also possesses certain potentially anti-
atherosclerotic properties in vitro [12]. Thus, interpretation on the global in vivo effects of LA on IFN-
γ secretion by CD4
+
 T cells is complex. 
IL-2 is produced mainly by activated Th1 cells and is an important regulator of the immune response 
and homeostasis. It also plays a central role in downregulating immune responses and its absence 
results in severe autoimmunity [14]. Interestingly, recent studies have indicated that a major 
function of the IL-2/IL-2 receptor system lies in directing development and function of T regulatory 
cells (Tregs) [15]. In atherosclerotic diseases, high levels of IL-2 have been detected in atheromatous 
plaques [16] but despite this evidence, the role of IL-2 in the pathogenesis and/or in the progression 
of various atherosclerotic diseases has not yet been determined. Our study suggest that the high 
levels of IL-2 associated with dyslipidemia could be  partially explained by an over secretion of this 
cytokine by CD46 co-activated CD4
+
 T cells. The fact that LA could trigger this effect might, again, 
reflect alterations of the CD46-mediated signalling pathways in these cells after LA, resulting in their 
incapacity to regulate the transition from innate to adaptive immunity (even in the presence of high 
IL-2 concentrations), therefore promoting pro-atherosclerotic effects and decreasing the efficacy of 
the treatment. 
We also observed a tendency for IL-17A secretion to be increased in LA patients compared to healthy 
donors, this effect being more marked after CD46 co-activation. This result might reflect the 
tendency of a CD4
+
 T cells pool to differentiate into Th17 lymphocytes in dyslipidemic patients. This is 
in accordance with previous observations by other groups which reported the presence of Th17 cells 
in human atherosclerotic lesions [17]. The role of IL-17A in atherosclerosis is still under debate, 
however the overall data indicate that enhanced IL-17A production associated with increased IL-10 
(regulatory Th17) and reduced IFN-γ will most probably limit lesion development and promote 
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plaque stability. In contrast, dual production of IL-17A and IFN-γ will most likely promote lesion 
progression and instability [18]. Intriguingly, recent evidences showed that both Th17 cells and 
immunosuppressive Tregs derived from naïve CD4
+
 cells and can be reciprocally induced, contingent 
upon the presence of either IL-6 or IL-2, respectively, in the presence of TGF [19]. Furthermore, it has 
been shown that Tregs exhibit “plasticity” and can become IL-17-producing cells after treatment with 
IL-6 both in vitro [20] and in vivo [21]. Therefore, considering our results and the increased secretion 
of IL-17A, IFN-γ and IL-10 together with the slight decrease in IL-6 secretion in CD46 co-activated 
CD4
+
 T cells from dyslipidemic patients, interpretation of the interplay between these cytokines, the 
resulting net effect on T cells differentiation and impact on atherosclerosis development is highly 
hazardous. We can however, speculate on the existence of a Th17 pool of T cells resulting from the 
IL-6 stimulated dedifferentiation of Tregs that would promote inflammation in dyslipidemic patients. 
This hypothesis is in range with previous results clearly associating high levels of circulating IL-6 with 
dyslipidemia and atherosclerosis development [22].  
TNF-α is produced by Th1 cells as well as macrophages and other cell types. TNF-α is a pro-
inflammatory cytokine and promotes several autoimmune diseases. In addition, TNF-α inhibits 
lipoprotein lipase, leading to hypertriglyceridemia and reduced fatty acid oxidation, and stimulates 
production of oxygen and nitrogen radicals [23]. Here, we observed a slight increase of TNF-α 
secretion by activated and co-activated CD4
+
 T cells in LA patients before treatment which is in line 
with previous observations. Interestingly, following LA, patients presented a level of secretion 
comparable to healthy donors, suggesting that LA could be responsible for the removal of TNF-α 
secretion stimulators, therefore reducing its pro-inflammatory and pro-atherogenic effects in 
dyslipidemic patients. 
We did not observe any significant changes in IL-6 secretion by activated CD4
+
 T cells in our 
conditions, but a tendency for a decrease in LA patients before and after treatment compared to 
controls. It is surprising since elevated circulating IL-6 rates have been clearly associated with 
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dyslipidemia and the progression of atherosclerosis. On the other hand, several types of immune 
cells secrete IL-6, including Th2 lymphocytes. Moreover, IL-17A acts on a variety of cells to induce the 
production of cytokines, including IL-6 and TNF-α [24]. Therefore, this result tends to suggest that 
CD4
+
 T cells are not involved in the increased circulating IL-6 rates observed in patients with 
dyslipidemia. However, high levels of IL-6 in dyslipidemic patients could be responsible for the 
dysregulation of CD4
+
 T cells activation and induction. 
Anti-inflammatory cytokine IL-10 secretion by CD4
+
 T cells tends to increase after CD46 co-
activation and LA amplifies this effect 
We also measured IL-10, a cytokine that is mainly produced by Th2 lymphocytes, and to a lesser 
extent by monocytes, macrophages and activated T lymphocytes. IL-10 inhibits the production of 
chemokines by Th1 lymphocytes (IFN-γ, TNF-α, IL-2 and IL-3) and macrophages (IL-1, IL-6, IL-8, GM-
CSF, TNF-α). In opposition with IL-6, IL-10 gene transfer can significantly reduce the atherosclerotic 
plaque area and the macrophage infiltrated area and decrease apoptosis of cells from the lipid core, 
thereby reducing the risk of plaque rupture [25]. A study by Mallat et al. also demonstrated other 
relevant proof of the anti-inflammatory and immunosuppressive activity of IL-10 [26]. Nevertheless, 
it is still unclear whether high plasma levels of IL-10 are to be considered as a marker of anti-
inflammatory patterns (with a reduced likelihood of developing atherosclerosis), or conversely 
whether they are counter regulatory consequences related to primitive pro-inflammatory patterns 
[27]. The latter is more likely to contribute to the effects of dyslipidemia and LA on IL-10 secretion 
pattern after CD46 co-activation observed in this pilot study. Actually, another major source of IL-10 
is CD4
+
 Treg cells, thus the observed increase in IL-10 secretion in dyslipidemic patient’s co-activated 
T cells could reflect an attempt of these cells to switch from IFN-γ to IL-10 secretion, meaning from a 
Th1 to a Treg phenotype. However, the high levels of IFN-γ observed in the same condition suggest 
that this transition, essential for the regulation of innate and adaptive immune response does not 
occur in our model. This hypothesis, again, is in line with potential alterations in the CD46-mediated 
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signalling events in dyslipidemic CD4
+
 T cells after CD46 co-activation. Interestingly, it has been 
demonstrated that IL-10-mediated suppression of Th1 cells is achieved not only through IL-10 
produced extrinsically, but also through a negative feedback loop that induces ‘‘intrinsic’’ IL-10 
expression in cells also expressing IFN-γ during Th1 lineage differentiation. Moreover, it was reported 
that CD46 and IL-2-induced switching is defective in rheumatoid arthritis (RA) patients. T cells from 
patients with RA fail to shut down IFN-γ production upon CD46-activation, and lack the IFN-γ
-
 IL-10
+
 
cell subpopulation. As a consequence of this intrinsic cell defect, differentiating Th1 cells produce up 
to 20 times more IFN-γ compared to T cells from healthy individuals [28]. In addition, and in contrast 
to T cells from healthy individuals, the IFN-γ
+
 IL-10
+
 T cells from RA patients lack suppressor functions. 
Thus, we postulate that a similar mechanism could occur in dyslipidemic patients and that this 
particular phenotype is further modulated by intrinsic effects of LA. 
Complement-NLRP3 inflammasome axis could be involved in the particular cytokines secretion 
pattern in CD4
+
 T cells from LA patients before and after treatment 
It has been recently demonstrated that certain LA systems are  associated with an elevated 
circulating rate of alternative complement products C3a and Bb [29]. The complement system has 
recently begun to attract interest as a therapeutic target since complement components might 
enhance production of IL-1b [30] which is critically involved in several inflammatory diseases  [30]. 
However, it is unknown whether, or how, complement and IL-1b are linked. One possibility is that 
the interaction of complement system with TLRs on phagocytes enhances the activation of the NLRP3 
inflammasome and promotes maturation of the pro-inflammatory cytokines IL-1b and IL-18 [31]. This 
theory brings a new perspective to the search for therapeutic targets in diseases characterized by 
abnormal complement and IL-1b activity, including dyslipidemia and atherosclerosis progression [32]. 
On the other hand, it is well established that CD4
+
 T cells depend on the activation of T cell–
expressed complement receptors binding C3 activation fragments for normal Th1 induction and 
contraction [28, 32]. Indeed, C3- and CD46-deficient patients suffer from recurrent infections and 
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have severely reduced Th1 responses. Conversely, uncontrolled intracellular C3 activation (or 
dysregulated CD46 engagement) in T cells contributes to hyperactive Th1 responses observed in 
autoimmunity [28, 31-33]. Recently, Arbore et al. demonstrated the existence of a similar mechanism 
involving C5 and C5a receptors (C5aR) in human CD4
+
 T cells, thus establishing the existence of a 
crucial link between intracellular complement products synthesis and the regulation of innate and 
adaptive immunity through the regulation of IFN-γ secretion by CD4
+
 T cells. Surprisingly, they further 
observed an enrichment of transcripts associated with inflammasome activation, including NLRP3 
and IL-1b, in CD4
+
 T cells co-activated with CD3 and CD46. Finally, their results demonstrated that the 
regulated cross-talk between intracellularly activated complement components (the “complosome”) 
and the NLRP3 inflammasome is fundamental to human Th1 induction and regulation, suggesting 
that the complement-NLRP3 axis in T cells may represent a novel therapeutic target for the 
modulation of Th1 activity in autoimmunity and infection. 
We did not analyse the expression of complement components or NLRP3 in our model, neither the 
secretion of IL-1b. Therefore, we can only hypothesize on the role of the complement and 
complement-NLRP3 axis in the effects of dyslipidemia and LA on CD4
+
 T cells cytokines secretion 
pattern. However, it is not unreasonable to think that this major newly described complement-
inflammasome crosstalk could be of fundamental interest in targeting pro-inflammatory components 
associated with dyslipidemia and the development of atherosclerosis.  
CONCLUSION 
Using anti-CD3 antibodies alone or a combination of anti-CD3 + anti-CD46 antibodies for activation, 
we observed a deep remodelling of CD4
+
 T cells cytokines secretion patterns in LA patients compared 
to healthy donors. These alterations include higher IFN-γ, IL-2, IL-17A and IL-10 secretion rates after 
CD46 co-activation. This suggest a defect in the CD46 co-activated CD4
+
 T cells lineage differentiation 
and the incapacity of these cells to acquire a full regulatory phenotype (Treg), therefore maintaining 
a Th1 response and a pro-inflammatory environment, which in turn promotes dyslipidemia and 
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atherosclerotic diseases. These results also raise questions on the lineage differentiation of CD4
+
 T 
cells and on the role of the NLRP3 inflammasome and complement system in LA patients. Moreover, 
we demonstrated that LA itself also modifies CD4
+
 T cells phenotype and activation in LA patients: LA 
tended to amplify the over secretion of pro-inflammatory cytokines but had minor impact on anti-
inflammatory cytokines.   
While our results are not sufficient to clearly establish a beneficial or unfavourable role of LA on 
immunity, it seems that this technique tends to increase the effects already induced by dyslipidemia 
on CD4
+
 T cells activation pattern. It is reasonable to believe that behind its LDL-lowering effect, LA 
could also provide a supportive modulation system for circulating cytokines in dyslipidemic patients  
and improve the efficiency of the treatment. However, more extensive evaluations are necessary to 
clearly define the role of LA in this context.  
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FIGURES 
Figure 1: 
  
 
 
 
 
 
 
 
Figure 1: CD4
+
 T cells pro-inflammatory cytokines secretion in dyslipidemic patients is altered and 
this effect tends to be amplified by LDL-a. 
Isolated CD4
+
 T cells from dyslipidemic and healthy donors were activated with TCR alone (CD3), co-
activated with CD3 and CD46 antibodies or maintained non-activated for 36h, then the 
concentrations of secreted cytokines were measured by cytometry. 
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Figure 2:  
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Figure 2: Isolated CD4
+
 T cells IL-6 secretion profiles 
A: Isolated CD4
+
 T cells from dyslipidemic and healthy donors were activated with TCR alone (CD3), 
co-activated with CD3 and CD46 antibodies or maintained non-activated for 36h, then the 
concentrations of secreted IL-6 were measured by cytometry. B: A segregation of 2 different sub-
populations between dyslipidemic patients was observed regarding LDL-a effects on IL-6 secretion. 
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Figure 3: 
 
 
Figure 3: Isolated CD4
+
 T cells anti-inflammatory cytokines secretion profile in dyslipidemic 
patients.  
Isolated CD4
+
 T cells from dyslipidemic and healthy donors were activated with TCR alone (CD3), co-
activated with CD3 and CD46 antibodies or maintained non-activated for 36h, then the 
concentrations of secreted cytokines were measured by cytometry. 
  
